About Verve Biosciences
Verve Biosciences is a Healthcare company based in Delhi (India) founded in 2018. Specialty pharmaceutical consultancy delivering hard-to-access drugs to patients worldwide. It operates on a D2C and B2B model. Its Indian entity Verve Biosciences Private Limited reported revenue of ₹31.3 Lakh. Verve Biosciences offers products and services including Sandostatin, Lysodren, BESPONSA, IMBRUVICA, and KEYTRUDA. Its focus areas include Biotechnology, Oncology, Cancer Medicine Distribution and Pharmaceuticals.
Company details
Verve Biosciences is a pharmaceutical consultancy based in New Delhi, India, that focuses on sourcing and distributing rare medicines for cancer, diabetes, and other diseases. They operate by connecting patients with essential drugs through a dedicated service model, ensuring global access via online and direct channels. The company handles various treatments, collaborates with healthcare providers, and maintains efficient delivery to improve patient outcomes, drawing from a wide range of oncology products.
- Headquarters Delhi, India
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cancermedicinesnetwork.com
- Legal Name Verve Biosciences Private Limited
- Date of Incorporation 24 Feb, 2009
- Jurisdiction Pune, Maharashtra, India
- Annual Revenue₹31.3 Lakh
FY 2026 · -4% YoY
- Net Profit₹2.7 Lakh
FY 2026 · 8% margin
- EBITDA₹4.1 Lakh
FY 2026 · 13% margin
Associated legal entities of Verve Biosciences
Verve Biosciences operates through Verve Biosciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Verve Biosciences Private Limited CIN U52399PN2009PTC207232 | Active | 24 Feb 2009 | Pune, Maharashtra | ₹0.3 Cr | 2 | View details |
Products & Services of Verve Biosciences
Verve Biosciences offers a comprehensive portfolio of products and services, including Sandostatin, Lysodren, BESPONSA, IMBRUVICA, and KEYTRUDA.
Treatment for acromegaly and related conditions
Medication for adrenal cortical carcinoma
Therapy for leukemia patients
Used in blood cancer treatments
Immunotherapy for various cancers
Targeted therapy for ovarian and breast cancer
Diabetes management drug
Treatment for diabetes and heart conditions
Board of directors of Verve Biosciences Private Limited (Verve Biosciences)
Verve Biosciences Private Limited is the primary company behind Verve Biosciences. The board of Verve Biosciences Private Limited currently have 2 directors; the longest-serving is Jayaraj Pralhad Kulkarni, appointed in 2021. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jayaraj Pralhad Kulkarni DIN 09076347 | Director | 22 Feb 2021 | 5 yrs 8 mo | Verve Biosciences Private Limited |
| Manjiri Jayaraj Kulkarni DIN 08290829 | Director | 22 Feb 2021 | 5 yrs 8 mo | Verve Biosciences Private Limited |
Financials of Verve Biosciences
Figures of Verve Biosciences Private Limited, the primary company behind Verve Biosciences, for FY 2026. Revenue was ₹31.3 Lakh (-4% year on year). Net profit was ₹2.7 Lakh (8% margin). EBITDA was ₹4.1 Lakh (13% margin). Revenue has grown at a compounded annual rate of +7% over three years and +15% over five years.
- ₹31.3 LakhRevenue · FY 2026 · -4% YoY
- ₹2.7 LakhNet profit · 8% margin
- ₹4.1 LakhEBITDA · 13% margin
- ₹1 LakhPaid-up capital
- +7%Revenue CAGR, 3 years
- +15%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Verve Biosciences Private Limited are on its company page.
Detailed financial statements for Verve Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Verve Biosciences
Verve Biosciences was founded in 2018.
Verve Biosciences is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
The primary company behind Verve Biosciences, Verve Biosciences Private Limited, reported revenue of ₹31.3 Lakh for FY 2026, down 4% year on year.
Verve Biosciences is a pharmaceutical consultancy based in New Delhi, India, that focuses on sourcing and distributing rare medicines for cancer, diabetes, and other diseases. They operate by connecting patients with essential drugs through a dedicated service model, ensuring global access via online and direct channels. The company handles various treatments, collaborates with healthcare providers, and maintains efficient delivery to improve patient outcomes, drawing from a wide range of oncology products.
Verve Biosciences offers Sandostatin, Lysodren, BESPONSA, IMBRUVICA, and 4 more products and services.
Verve Biosciences operates through Verve Biosciences Private Limited.
The legal entities of Verve Biosciences currently have 2 directors, including Jayaraj Pralhad Kulkarni, Manjiri Jayaraj Kulkarni.